[1]
Anandakumar, K.; Abirami, G.; Murugan, S.; Ashok, B. RP-HPLC method for simultaneous estimation of Lamivudine, Tenofovir Disoproxil Fumarate and Efavirenz in tablet formulation. J. Anal. Chem., 2013, 68(9), 815-821.
[2]
Bhavsar, D.S.; Patel, B.N.; Patel, C.N. RP-HPLC method for simultaneous estimation of Tenofovir Disoproxil Fumarate, Lamivudine, and efavirenz in combined tablet dosage form. Pharm. Methods, 2012, 3(2), 73-78.
[3]
Mallikarjuna Rao, N.; Gowri Sankar, D. Development and validation of stability-indicating HPLC method for simultaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form. FJPS, 2015, 1(2), 73-77.
[4]
Rao, S.; Kumar, N.; Srilekha, K.; Kumari, A. Stability indicating method for the simultaneous estimation of Tenofovir, Emtricitabine and Efavirenz in pure and pharmaceutical dosage form by RP-HPLC. IJARSE, 2016, 5(5), 188-200.
[5]
Kavitha, K.Y.; Geetha, G.; Hariprasad, R.; Venkatnarayanan, R.; Kaviarasu, M. Development and validation of RP-UPLC analytical method for simultaneous estimation of emtricitabine, rilpivirine, Tenofovir Disoproxil Fumarate and its pharmaceutical dosage forms. IRJP, 2013, 4(1), 150-155.
[6]
Ramaswamy, A.; Dhas, A.S.A.G. Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC. Arab. J. Chem., 2014, 11(2), 275-281.
[7]
Reddy.Yenumula, B.R. Reddy.Singampalli, M.; Reddy.Challa, B.S. Simultaneous estimation of emtricitabine and Tenofovir Disoproxil Fumarate in tablet dosage form by reverse phase high-performance liquid chromatography. IJAT, 2015, 1(1), 6.
[8]
Devrukhakar, P.S.; Borkar, R.; Shastri, N.; Surendranath, K.V. A Validated stability-indicating RP-HPLC method for the simultaneous determination of tenofovir, emtricitabine, and a efavirenz and statistical approach to determine the effect of variables. ISRN Chromatography, 2013, 2013, 1-8.
[9]
Vanitha, C.; Kumar, P.P.; Rajani, S.V.; Swarnalatha, G.; Sekar, V. Simultaneous estimation of emtricitabine and Tenofovir Disoproxil Fumarate in a tablet dosage form by RP-HPLC method. IJPDT, 2014, 4(4), 279-283.
[10]
Chaitanya, M.; Swathi, K.; Raju, P.N.; Swathi, K. Method development and validation of efavirenz by RP-HPLC method. IJPRHS, 2015, 3(3), 763-768.
[11]
Matthews, C.; Woolf, E.; Mazenko, R.; Haddix-Wiener, H.; Chavez-Eng, C.; Constanzer, M.; Doss, G.; Matuszewski, B. Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection. J. Pharm. Biomed. Anal., 2002, 28(5), 925-934.
[12]
Pradeep Kumar, S.C.D.; Kushnoor, A. Validation and stability of RP-HPLC method for the determination of efavirenz as bulk drug and in pharmaceutical formulations. Int. J. Pharma Bio Sci., 2011, 2(4), 220-231.
[13]
Sandhya, K.; Reddy, N.N.; Manohar, R.; Rajashekar, P. RP-HPLC method development and validation for simultaneous estimation of Lamivudine, zidovudine and nevirapine in tablet dosage form. Indo Am. J. pharm. res., 2014, 4(4), 2133-2140.
[14]
Sarasa-Nacenta, M.a.; Lopez-Púa, Y.; Lopez-Cortes, L.F.; Mallolas, J.; Gatell, J.M.; Carne, X. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl., 2001, 763(1), 53-59.
[15]
Viana, O.D.S.; Medeiros, F.P.M.; Grangeiro-Júnior, S.; Albuquerque, M.M.; Soares, M.F.L.R.; Soares-Sobrinho, J.L.; Alves, L.D.S.; Rolim, L.A.; Silva, K.E.R.D.; Rolim-Neto, P.J. Development and validation of a HPLC analytical assay method for efavirenz tablets: a medicine for HIV infections. Braz. J. Pharm. Sci., 2011, 47(1), 97-102.
[16]
Purnima, B.V.; Reddy, T.V.B.; Rao, Y.S.; Ramu, G.; Ramachandran, D. Stability indicating RP-UPLC method for assay of emtricitabine and Tenofovir Disoproxil Fumarate in bulk and dosage forms. Am. J. Analyt. Chem., 2015, 6(10), 807-821.
[17]
Psrchnp, V.D.; Rao, A.L. Stability-indicating RP-HPLC method for the simultaneous estimation of efavirenz, tenofovir and emtricitabine in pharmaceutical formulations. IJPP, 2014, 1(1), 1-17.
[18]
White, K.L.; Kulkarni, R.; McColl, D.J.; Rhee, M.S.; Szwarcberg, J.; Cheng, A.K.; Miller, M.D. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients. Antivir. Ther., 2015, 20(3), 317-327.
[19]
Siddiqui, M.R.; AlOthman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arabian. J. Chem., 2017, 1, S1409-S1421.
[20]
AlOthman, Z.A.; Rahman, N.; Siddiqui, M.R. Review on pharmaceutical impurities, stability studies and degradation products. Rev. Adv. Sci. Eng., 2013, 2, 155-166.
[21]
Rahman, N.; Azmi, S.N.H.; Wu, H.F. The importance of impurity analysis in pharmaceutical products: An integrated approach. Accred. Qual. Assur., 2006, 11, 69-74.